Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells

Blood

Volumn 111, Issue 3, 2008, Pages 1287-1294

  Secchiero, Paola ^a   Corallini, Federica ^a   Rimondi, Erika ^a   Chiaruttini, Cristina ^a   Grazia Di Iasio, Maria ^a   Rustighi, Alessandra ^b   Del Sal, Giannino ^b   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUTLIN 3; OSTEOPROTEGERIN; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG INHIBITION; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 38949092911     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-092031     Document Type: Article

References (48)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
2. Zauli G, Secchiero P. The role of theTRAIL/TRAIL-receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006;17:245-257.
3. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62:1619-1623.
4. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86:269-279.
5. Pettersen I, Bakkelund W, Smedsrod B, Sveinbjornsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25:3809-3816.
6. Malyankar U, Scatena M, Suchland K, Yun T, Clark E, Giachelli C. Osteoprotegerin is an avb3-induced, NF-kB-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-20962.
7. Pritzker LB, Scatena M, Gianchelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis inducing ligand in the human microvascular endothelial cell survival. Mol Biol Cell. 2004;15:2834-2841.
8. Kobayashi-Sakamoto M, Hirose K, Nishikata M, Isogai E, Chiba I. Osteoprotegerin protects endothelial cells against apoptotic cell death induced by porphyromonas gengivalis cysteine proteinases. FEMS Microbiol Lett. 2006;264:238-245.
9. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006;169:2236-2244.
10. Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG): a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118:1901-1908.
11. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2003;8:2306-2310.
12. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001;264:169-184.
13. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 2005;65:1627-1630.
14. Vousden KH, Prives C. p53 and prognosis: new insights and further complexity. Cell. 2005;120:7-10.
15. Zauli G, Pandolfi A, Gonelli A, et al. TNF-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res. 2003;92:732-740.
16. Secchiero P, Gonelli A, Mirandola P, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood. 2002;100:2421-2429.
17. Secchiero P, Gonelli A, Celeghini C, et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood. 2001;98:2220-2228.
18. Secchiero P, Melloni E, Heikinheimo M, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood. 2004;103:517-522.
19. Zauli G, Visani G, Bassini A, et al. Nuclear translocation of protein kinase C-α and -ζ isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid (ATRA). Br J Haematol. 1996;93:542-550.
20. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
21. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
22. Secchiero P, Corallini F, Gonelli A, et al. Anti-angiogenic activity of the MDM2 antagonist nutlin-3. Circ Res. 2007;100:61-69.
23. Ray S, Shyam S, Fraizer GC, Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther. 2007;6:1368-1378.
24. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005;65:10637-10641.
25. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood. 2007;110:536-543.
26. Mangan SH, Campenhout AV, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res. 2007;76:494-505.
27. Tan M, Wang Y, Guan K, Sun Y. PTGF-b, a type b transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci U S A. 2000;97:109-114.
28. Dijsselbloem N, Goriely S, Albarani V, et al. A critical role for p53 in the control of NF-kB-dependent gene expression in TLR4-stimulated dendritic cells exposed to genistein. J Immunol. 2007;178:5048-5057.
29. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. Nutlin-3 inhibits the NF kappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle. 2007;6:2178-2185.
30. Toruner M, Fernandez-Zapico M, Sha JJ, Pham L, Urrutia R, Egan LJ. Anti-anoikis effect of nuclear factor-kB through upregulated expression of osteoprotegerin, Bcl-2 and IAP-1. J Biol Chem. 2006;281:8686-8696.
31. Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J. Statins decrease TNFalpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol. 2007;73:77-83.
32. Mosckovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006;66:10671-10676.
33. LaRusch GA, Jackson MW, Dunba JD, Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1A and Hdm2. Cancer Res. 2007;67:450-454.
34. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121.
35. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1- positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-827.
36. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62:1619-1623.
37. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63:912-916.
38. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and RANKL or TRAIL: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007;282:31601-31609.
39. Komarova EA, Krivokrysenko V, Wang K, et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 2005;19:1030-1032.
40. Weisz L, Damalas A, Liontos M, et al. Mutant p53 enhances nuclear factor KB activation by tumor necrosis factor A in cancer cells. Cancer Res. 2007;67:2396-2401.
41. Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood. 2004;104:1490-1497.
42. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150-3159.
43. Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106:3609-3617.
44. Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (BCLL). Blood. 2006;107:4122-4129.
45. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. Mdm2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006;107:4109-4114.
46. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108:993-1000.
47. Sarek G, Kurki S, Enback J, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest. 2007;117:1019-1028.
48. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13:23-31.